
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Chris Topoleski, director of federal regulatory affairs for ASHP discusses how the federal compounding law will affect health-system pharmacists.
Chris Topoleski, director of federal regulatory affairs for ASHP discusses how the federal compounding law will affect health-system pharmacists.
This video was taken at ASHP's Summer Meetings and Exposition in June 2015.






